Novel, Potent, and Orally Bioavailable LSD1 Inhibitors Induce Fetal Hemoglobin Synthesis in a Sickle Cell Disease Mouse Model

Researchers utilized structure-aided drug design to develop potent new reversible lysine-specific demethylase 1 inhibitors’ (LSD1i’s) leading to robust γ-globin expression in vitro.